Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

LONDON, June 18, 2018 /PRNewswire/ -- Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

Download the full report: https://www.reportbuyer.com/product/5439568

Summary

Psoriasis is a chronic, autoimmune, relapsing, inflammatory disease triggered by deregulated thymus-derived cells (T cells), resulting in inflammation and benign hyperplasia of keratinocytes within the skin affecting around 2-3% of the world's population. Manifestations of affected skin are red thickened plaques with an overlying silver-white scale, which significantly impairs the patient's physical and mental wellbeing.

The Asia-Pacific (APAC) psoriasis market is forecast to grow from $933.1m in 2017 to $1,997.3m in 2024, at a compound annual growth rate (CAGR) of 11.5%. Over the forecast period the prevalence of psoriasis is expected to increase significantly across the APAC markets, mainly due to alterations in environmental and lifestyle risk factors.

While psoriasis is likely caused by a genetic predisposition, other intrinsic and environmental factors, including those linked to lifestyle, play a role in the development and progression of disease, including smoking, alcohol consumption, and obesity. The rising prevalence, together with an increase in the diagnosis rate, heightened awareness and rising demand for improved healthcare infrastructure are expected to contribute to market growth.

The treatment landscape of psoriasis is dense and complex, with treatment options prescribed based on the severity of the indication. More than 80% of psoriasis patients fall under the category of mild or moderate, whose first line of treatment is topical drugs or phototherapy, or a combination of both. For severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as the first line. However, toxicity concerns mean that they cannot be prescribed for long durations.

Biologics have emerged as highly potent treatment options in patients for whom traditional systemic therapies fail to achieve an adequate response, or are not tolerated owing to adverse effects, or are unsuitable owing to comorbidities. New molecules are continually being added to this group. TNF-? inhibitor were the first class of biologics approved for the treatment of psoriasis and has long dominated the therapeutic space. However, the dominance of TNF-? inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab will be challenged during the forecast period by the highly effective IL-17 and IL-23 inhibitor therapies.

The key research inclusions of the report "Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market" are:

- Key reasons driving the psoriasis market in the five Asia-Pacific markets: India, China, Australia, South Korea and Japan.
- Introduction to psoriasis, detailing the epidemiology, symptoms, etiology, pathophysiology, and diagnosis for patients.
- Comprehensive Heatmap and detailed analysis of the drugs currently marketed for psoriasis.
- Analysis of the pipeline for psoriasis, by stage of development, molecule type, program type, mechanism of action and molecular target.
- Assessment of promising late-stage pipeline molecules in terms of their potential competitive strength.
- Forecasts for the psoriasis market, including epidemiology, treatment usage patterns, pricing and market size for the 2017-2024 period.
- Key market drivers and barriers for the psoriasis market.
- Major deals that have taken place in the global psoriasis market.

Scope
- The Asia-Pacific psoriasis market will be valued at $1,997.3m in 2024, growing from $933.1m in 2017, at a compound annual growth rate (CAGR) of 11.5%.
- What are the key factors driving the Asia-Pacific psoriasis treatment market?
- How will novel IL-23 inhibitor therapy Tremfya, which holds first-to-market advantage, contribute to growth?
- What will be the impact of the new IL-17 and IL-23 inhibitor therapies?
- How will branded therapies be affected by upcoming pipeline therapies?
- The psoriasis pipeline contains a range of molecule types and molecular targets, including those that are well established in psoriasis and novel target therapies.
- Which molecular targets appear most frequently in the pipeline?
- Is there potential for pipeline molecules to address unmet needs within the psoriasis market?
- Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- Which classes of drugs are most prominent in the pipeline?
- How will the approval of risankizumab and tildrakizumab, which hold a key advantage in terms of dosing schedule over IL-23 competitor Tremfya, affect the competitive landscape?
- Various drivers and barriers will influence the market over the forecast period.
- What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?
- What licensing and co-development deals have occurred within this therapy area since 2007?

Reasons to buy
- Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.
- Visualize the composition of the psoriasis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the psoriasis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict psoriasis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the psoriasis deals landscape by analyzing trends in licensing and co-development deals.

Download the full report: https://www.reportbuyer.com/product/5439568

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com